Mizuho Initiates Coverage On Enliven Therapeutics with Buy Rating, Announces Price Target of $34
Portfolio Pulse from Benzinga Newsdesk
Mizuho analyst Salim Syed initiates coverage on Enliven Therapeutics (ELVN) with a Buy rating and a price target of $34.

April 09, 2024 | 12:11 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Mizuho has initiated coverage on Enliven Therapeutics with a Buy rating and a price target of $34.
Analyst ratings, especially from reputable firms like Mizuho, can significantly influence investor sentiment and stock prices. A Buy rating combined with a substantial price target suggests a strong bullish outlook for Enliven Therapeutics, likely leading to increased investor interest and potentially higher stock prices in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100